| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
The specific molecular targets of N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide are not well-defined in publicly available sources. As an amide derivative of a fatty acid, it may interact with various receptors and enzymes, including cannabinoid receptors, GPR55, or fatty acid amide hydrolase (FAAH). Fatty acid amides are endogenous signaling molecules that can modulate pain, inflammation, and other physiological processes.
|
|---|---|
| ln Vitro |
In vitro, N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide may exhibit biological activities typical of fatty acid amides. These can include anti-inflammatory effects, such as the inhibition of pro-inflammatory cytokine production, and analgesic effects, such as the modulation of pain signaling pathways. Its specific potency and efficacy would need to be determined in appropriate cell-based assays.
|
| ln Vivo |
In vivo, compounds related to fatty acid amides have demonstrated various pharmacological effects in animal models. These can include anti-inflammatory, analgesic, and neuroprotective activities. The specific in vivo effects of N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide would need to be investigated in relevant disease models.
|
| Enzyme Assay |
The biochemical activity of N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be assessed using in vitro assays. Its binding affinity for potential targets, such as cannabinoid receptors, can be measured in radioligand binding assays. Its ability to inhibit enzymes like FAAH can be assessed in enzyme activity assays.
|
| Cell Assay |
The cellular activity of N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is evaluated in cell lines relevant to its potential targets. Cells are treated with the compound, and its effects on signaling pathways, cytokine production, and cell viability are measured. The compound's ability to modulate pain-related signaling can be assessed in neuronal cell models.
|
| Animal Protocol |
In animal studies, N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide would typically be administered to rodents via oral or intraperitoneal injection. In models of inflammation or pain, its effect on disease severity or pain behaviors would be assessed. Its pharmacokinetic properties and tissue distribution would also be evaluated.
|
| ADME/Pharmacokinetics |
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide has a molecular weight of approximately 400 g/mol. It is soluble in organic solvents such as DMSO and ethanol. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are characteristic of fatty acid amides and would need to be characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicology data for N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is not publicly available. As a research compound, its safety profile has not been established in formal toxicology studies. Its use is limited to research applications.
|
| References | |
| Additional Infomation |
It has been reported that Lepidium meyenii contains N-(3-methoxybenzyl)-(9Z,12Z,15Z)-octadecanetrienamide, and relevant data are available. See also: Lepidium meyenii root (partial).
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide (CAS: 883715-23-9) is a research compound used to study the biological activities of fatty acid amides. Its structural similarity to endogenous signaling molecules makes it a valuable tool for investigating the role of fatty acid amides in pain, inflammation, and other physiological processes. Further research is needed to fully characterize its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C26H39NO2
|
|---|---|
| Molecular Weight |
397.593367815018
|
| Exact Mass |
397.298
|
| CAS # |
883715-23-9
|
| PubChem CID |
73353637
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.961±0.06 g/cm3
|
| Boiling Point |
562.1±50.0 °C at 760 mmHg
|
| Flash Point |
293.8±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.516
|
| LogP |
7.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
29
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1C=CC=C(OC)C=1)NC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC
|
| InChi Key |
XKHCEDYSKNATME-YSTUJMKBSA-N
|
| InChi Code |
InChI=1S/C26H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-26(28)27-23-24-19-18-20-25(22-24)29-2/h4-5,7-8,10-11,18-20,22H,3,6,9,12-17,21,23H2,1-2H3,(H,27,28)/b5-4-,8-7-,11-10-
|
| Chemical Name |
(9Z,12Z,15Z)-N-[(3-methoxyphenyl)methyl]octadeca-9,12,15-trienamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~251.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5152 mL | 12.5758 mL | 25.1515 mL | |
| 5 mM | 0.5030 mL | 2.5152 mL | 5.0303 mL | |
| 10 mM | 0.2515 mL | 1.2576 mL | 2.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
